Pages that link to "Q46377291"
Jump to navigation
Jump to search
The following pages link to Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. (Q46377291):
Displaying 11 items.
- Personalized medicine: Genetic risk prediction of drug response (Q38756015) (← links)
- One amino acid makes a difference-Characterization of a new TPMT allele and the influence of SAM on TPMT stability (Q38809535) (← links)
- Bringing a genomic perspective to the safety of drug treatment in oncology. (Q39241906) (← links)
- Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. (Q48263723) (← links)
- Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia. (Q52665811) (← links)
- Multiplex assessment of protein variant abundance by massively parallel sequencing (Q57475860) (← links)
- Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring (Q57817595) (← links)
- Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment (Q64077129) (← links)
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update (Q64121167) (← links)
- NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease (Q89623664) (← links)
- PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients (Q91620871) (← links)